Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.

Jonathon B CohenLai WeiKami J MaddocksBeth ChristianLeonard T HeffnerAmelia A LangstonMary Jo LechowiczPierluigi PorcuChristopher R FlowersSteven M DevineKristie A Blum

Published in: Cancer (2019)

This doublet was found to be tolerable and effective, but patients must be monitored closely for pulmonary toxicity. The authors currently are evaluating this doublet in combination with nivolumab.

Keyphrases

hodgkin lymphoma
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
pulmonary hypertension
peritoneal dialysis
oxidative stress
open label
clinical trial
radiation therapy
patient reported outcomes
locally advanced